Shares in Novo Nordisk opened nearly 3 % lower on the Copenhagen Stock Exchange this morning. The slide comes after the Danish pharmaceutical company — alongside Eli Lilly and Company — entered into a major agreement with the Donald Trump administration in the United States.
What the Deal Involves
Under the agreement, Novo Nordisk and Eli Lilly will be permitted to sell their obesity-treating drugs (notably those based on GLP-1 compounds) through US public insurance programmes: Centres for Medicare & Medicaid Services (Medicare) and Medicaid.
In return, the companies agree to significantly lower prices. The US White House fact sheet indicates that upfront cash‐pay prices will drop — for example from up to US $1,350/month to around US $350/month on a dedicated platform (“TrumpRx”) for uninsured or out-of-pocket patients.
For Medicare and Medicaid, the deal foresees substantially reduced pricing and broader patient access (including through federal coverage of obesity medications which had previously been excluded in many cases).
Why the Stock Fell
On the surface it seems like a big market opportunity — more patients, more coverage — but investors reacted with caution. Here’s why:
- Lower prices reduce margins. Novo Nordisk itself has trimmed its growth outlook, citing these pricing pressures.
- The deal introduces complexity. Accessing heavily regulated US public programmes often comes with delayed timelines, rebates, additional administrative burden.
- The US remains a key growth engine for Novo; any setback here has out-sized implications for its global ambitions.
Analysts Weigh In
Equity analysts offer a nuanced view:
- Henrik Hallengreen Laustsen at Jyske Bank sees the deal as positive: it opens access to a large new patient base (US citizens aged 65+ via Medicare, and lower-income groups via Medicaid) — potentially outweighing the price hit.
- Søren Løntoft at Sydbank warns the effect on earnings will hit early: he labels the price drop as “moderate” but expects a visible negative earnings impact when the reductions kick in.
- Lars Skovgaard Andersen at Danske Bank appreciates the removal of uncertainty (investors dislike surprises) but flags that Novo’s core business must perform — and recent results show disappointments.
Strategic Implications for Novo Nordisk
Here are the key strategic themes for Novo going forward:
- Scale vs price trade-off: By gaining coverage in Medicare/Medicaid and a direct-to-consumer path via TrumpRx, Novo can scale its obesity drug portfolio. But scale only matters if unit economics remain viable.
- US dependency risk: Novo is heavily exposed to the US GLP-1 market. Any disruption (pricing, regulatory, competition) carries outsized risk.
- Competition heating up: With Eli Lilly and others in the race, pricing pressure is intensifying globally. Lower US prices may exert downward pressure elsewhere.
- R&D and pipeline: Lower revenue growth in high-margin areas can squeeze R&D investment. Novo must assure investors its innovation engine remains strong.
- Nordic/Home market strength: Investors in Nordic markets will watch how Novo balances US commitments with maintaining growth, margins and innovation in its home region and other geographies.
Bottom Line
The agreement with the Trump administration is a double-edged sword for Novo Nordisk. On one hand, it unlocks a vast new market and removes uncertainty around access in US public healthcare programmes. On the other, it compresses pricing, reduces margin potential and raises expectations that growth must now come from volume, not just price or premium positioning.
For Nordic investors in particular, this is a turning point: the era where pricing power alone propelled growth may be over. Execution, scale, cost discipline and the next wave of products will determine whether Novo recaptures its former growth trajectory.
In short: the deal is strategically significant — but it comes with a clear cost. Novo’s upcoming earnings and US execution will be among the most important cross-border metrics for 2026-27.